Formed in 2012, DeuteRx is a virtual biopharmaceutical company focused on improving racemic drugs for patients. The team has pioneered the use of Deuterium-Enabled Chiral Switching (DECS) to isolate a single stereoisomer from a mixture of interconverting stereoisomers.